Tobramycin and FDA-Approved Iron Chelators EliminatePseudomonas aeruginosaBiofilms on Cystic Fibrosis Cells

The ΔF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability

(2008) Sophie Moreau-Marquis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Lung Function from Infancy to the Preschool Years after Clinical Diagnosis of Cystic Fibrosis

(2008) Wanda J. Kozlowska et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

In Vitro Analysis of Tobramycin-Treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells

(2008) G. G. Anderson et al.   INFECTION AND IMMUNITY

Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa

(2008) M. Halwani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Chelated iron sources are inhibitors ofPseudomonas aeruginosabiofilms and distribute efficiently in anin vitromodel of drug delivery to the human lung

(2008) D.J. Musk et al.   JOURNAL OF APPLIED MICROBIOLOGY

The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent

(2008) E. Banin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA